10.1016/j.jacbts.2018.09.004 28
Retrieved from Novo Nordisk-e
While animal studies and early clinical reports are promising, its important to note that BPC-157 peptide therapy is not yet FDA-approved for weight loss or any specific medical condition, and large-scale human studies are still needed
If you are already taking Wegovy and find that your IBS symptoms have become significantly worse or unmanageable despite supportive measures, contact your prescriber to discuss whether dose adjustment, temporary interruption, or alternative weight management strategies might be more appropriate
By targeting obesity first, healthcare providers can potentially improve or even resolve associated conditions like type 2 diabetes, hypertension, and dyslipidemia, she said